Evaluation of Calu-3 cell lines as an <i>in vitro</i> model to study the inhalation toxicity of flavoring extracts

Ji, Xiaoli; Sheng, Yunhua; Guan, Ying; Li, Yinxia; Xu, Yuqiong; Tang, Liming

doi:10.1080/15376516.2021.1977880

Cited by 4 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it is of great significance to explore the ability of NPs to transport across cell membranes. Calu-3 cells, a type of airway epithelial cell that secretes mucus [30], better mimics natural physiological environments and is widely used to assess the toxicity of nasal delivery systems [29,49,50]. The cells were treated with FITClabeled PLGA NPs, PLGA-PEG NPs and PLGA-PEG-Man NPs, and then observed by fluorescence inverted microscope.…”

Section: In Vitro Cytotoxicity and Cellular Uptakementioning

confidence: 99%

Immune cell receptor-specific nanoparticles as a potent adjuvant for nasal split influenza vaccine delivery

Li,

Xiu,

et al. 2024

Nanotechnology

View full text Add to dashboard Cite

Mucosal delivery systems have gained much attention as effective way for antigen delivery that induces both systemic and mucosal immunity. However, mucosal vaccination faces the challenges of mucus barrier and effective antigen uptake and presentation. In particular, split, subunit and recombinant protein vaccines that do not have an intact pathogen structure lack the efficiency to stimulate mucosal immunity. In this study, poly (lactic acid-co-glycolic acid-polyethylene glycol) (PLGA-PEG) block copolymers were modified by mannose to form a PLGA-PEG-Man conjugate (mannose modified PLGA-PEG), which were characterized. The novel nanoparticles (NPs) prepared with this material had a particle size of about 150 nm and a zeta potential of -15 mV, and possessed ideal mucus permeability, immune cell targeting, stability and low toxicity. Finally, PLGA-PEG-Man nanoparticles (PLGA-PEG-Man NPs) were successfully applied for intranasal delivery of split influenza vaccine in rat for the first time, which triggered strong systemic and mucosal immune responses. These studies suggest that PLGA-PEG-Man NPs could function as competitive potential nano-adjuvants to address the challenge of inefficient mucosal delivery of non-allopathogenic antigens.

show abstract

Section: In Vitro Cytotoxicity and Cellular Uptakementioning

confidence: 99%

Immune cell receptor-specific nanoparticles as a potent adjuvant for nasal split influenza vaccine delivery

Li,

Xiu,

et al. 2024

Nanotechnology

View full text Add to dashboard Cite

show abstract

“…Due to their origin, Calu-3 cells can produce mucus as well. The presence of tight junctions and the secretory activity highlight the potential of this cell line as a suitable in vitro model for studying the pulmonary drug absorption [97,98].…”

Section: Cell Culturementioning

confidence: 99%

Recent Options and Techniques to Assess Improved Bioavailability: In Vitro and Ex Vivo Methods

et al. 2023

View full text Add to dashboard Cite

Bioavailability assessment in the development phase of a drug product is vital to reveal the disadvantageous properties of the substance and the possible technological interventions. However, in vivo pharmacokinetic studies provide strong evidence for drug approval applications. Human and animal studies must be designed on the basis of preliminary biorelevant experiments in vitro and ex vivo. In this article, the authors have reviewed the recent methods and techniques from the last decade that are in use for assessing the bioavailability of drug molecules and the effects of technological modifications and drug delivery systems. Four main administration routes were selected: oral, transdermal, ocular, and nasal or inhalation. Three levels of methodologies were screened for each category: in vitro techniques with artificial membranes; cell culture, including monocultures and co-cultures; and finally, experiments where tissue or organ samples were used. Reproducibility, predictability, and level of acceptance by the regulatory organizations are summarized for the readers.

show abstract

Toxicological assessment of E-cigarette flavored E-liquids aerosols using Calu-3 cells: A 3D lung model approach

Effah,

Adragna,

Luglio

et al. 2023

Toxicology

View full text Add to dashboard Cite

Evaluation of Calu-3 cell lines as an in vitro model to study the inhalation toxicity of flavoring extracts

Cited by 4 publications

References 41 publications

Immune cell receptor-specific nanoparticles as a potent adjuvant for nasal split influenza vaccine delivery

Immune cell receptor-specific nanoparticles as a potent adjuvant for nasal split influenza vaccine delivery

Recent Options and Techniques to Assess Improved Bioavailability: In Vitro and Ex Vivo Methods

Toxicological assessment of E-cigarette flavored E-liquids aerosols using Calu-3 cells: A 3D lung model approach

Contact Info

Product

Resources

About